Cancer Family
Myeloid Neoplasm
CI-CAN-00000279Explore in graph →
HematologicNon-malignant1,102 active trials29 approved drugs653 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000279Explore in graph →
Clinical trials
4,789 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07301866 | A Study Testing an Improved Dose of UM171 to Help Make Cord Blood Transplants More Effective and Safe.(ECT-001-CB-013) | recruiting | Phase 1 / Phase 2 | 7 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06541249 | MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial(TREATMORE) | recruiting | Phase 2 | 54 | Icahn School of Medicine at Mount SinaiOTHER | 1 |
| Dec 17, 2025 |
| clinicaltrials |
| NCT05901974 | Venetoclax Combined With Azactidine in the Treatment of ALAL | recruiting | Phase 2 | 23 | Sheng-Li Xue, MDOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07153068 | SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies | recruiting | Phase 1 / Phase 2 | 12 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT06680752 | Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS | recruiting | Phase 1 / Phase 2 | 49 | ARCE Therapeutics, Inc.INDUSTRY | 1 | Dec 10, 2025 | clinicaltrials |
| NCT03300492 | Expanded Natural Killer Cells Following Haploidentical HSCT for AML/MDS | recruiting | Phase 1 / Phase 2 | 10 | University Hospital, Basel, SwitzerlandOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05194397 | Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors(IAMFIT) | recruiting | Phase 2 | 80 | Children's Hospital of PhiladelphiaOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT07255963 | Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL | recruiting | Phase 2 | 29 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07256210 | Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation | recruiting | Phase 2 | 15 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05566054 | Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia | recruiting | Phase 2 | 92 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT07238712 | Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor(APTBCy) | recruiting | Phase 2 | 60 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06532552 | Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid Leukemia | recruiting | Phase 2 | 172 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT06451861 | Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML | recruiting | Phase 2 | 240 | Guangdong Provincial People's HospitalOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT02143830 | HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy(RAFA) | recruiting | Phase 2 | 70 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT05031897 | Two Step Haplo With Radiation Conditioning | recruiting | Phase 2 | 63 | Thomas Jefferson UniversityOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT06265584 | Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant | recruiting | Phase 2 | 56 | University of Alabama at BirminghamOTHER | 1 | Oct 8, 2025 | clinicaltrials |
| NCT06315309 | Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant | recruiting | Phase 2 | 29 | University of Alabama at BirminghamOTHER | 1 | Oct 8, 2025 | clinicaltrials |
| NCT05211570 | AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 78 | AB ScienceINDUSTRY | 4 | Oct 2, 2025 | clinicaltrials |
| NCT04079179 | Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders(NACHO-COBI) | recruiting | Phase 2 | 90 | Carl AllenOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT05305859 | Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML | recruiting | Phase 2 | 30 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT04385290 | Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)(MOSAIC) | recruiting | Phase 1 / Phase 2 | 214 | Technische Universität DresdenOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT03850574 | Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia(TUSCANY) | recruiting | Phase 1 / Phase 2 | 240 | Aptose Biosciences Inc.INDUSTRY | 6 | Aug 26, 2025 | clinicaltrials |
| NCT07023588 | Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease | recruiting | Phase 2 | 70 | Yehui TanOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT07108530 | Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study | recruiting | Phase 2 | 50 | Shanxi Bethune HospitalOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT04440267 | Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage | recruiting | Phase 2 | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07078591 | Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML | recruiting | Phase 2 | 50 | Beijing 302 HospitalOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT06984536 | Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT | recruiting | Phase 2 | 40 | Peking University People's HospitalOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07028086 | VAM in Secondary AML, AML With Extramedullary Involvement, and Myeloid Sarcoma | recruiting | Phase 2 | 48 | Ruijin HospitalOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT06409936 | PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML(PEARL) | recruiting | Phase 2 | 160 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT06199557 | A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients(HUVAMER) | recruiting | Phase 1 / Phase 2 | 48 | Haukeland University HospitalOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT07036250 | Clinical Study of U32 in Patients With Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 20 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Jun 25, 2025 | clinicaltrials |
| NCT07028073 | A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 78 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 19, 2025 | clinicaltrials |
| NCT04687176 | Frontline Oral Arsenic Trioxide for APL | recruiting | Phase 2 | 100 | The University of Hong KongOTHER | 2 | Jun 12, 2025 | clinicaltrials |
| NCT06778187 | Oral-ATO for TP53-mutated Myeloid Malignancies | recruiting | Phase 2 | 30 | The University of Hong KongOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT07012447 | Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations | recruiting | Phase 2 | 32 | yuejun LiuOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT07007949 | a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia | recruiting | Phase 2 | 42 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06793410 | Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation | recruiting | Phase 2 | 100 | Vastra Gotaland RegionOTHER_GOV | 1 | Jun 5, 2025 | clinicaltrials |
| NCT06130579 | Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT | recruiting | Phase 2 | 35 | Peking University People's HospitalOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT06757855 | Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML | recruiting | Phase 1 / Phase 2 | 29 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT06982274 | Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic Leukemia(IC-APL2020) | recruiting | Phase 2 | 115 | Instituto do Cancer do Estado de São PauloOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT06696183 | Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment(SEQUENCE) | recruiting | Phase 2 | 60 | Technische Universität DresdenOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT06869265 | Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia | recruiting | Phase 2 | 56 | Peking University People's HospitalOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT06972641 | Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation | recruiting | Phase 2 / Phase 3 | 126 | Ruijin HospitalOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT06138990 | Pharmacoscopy-guided Clinical Standard-of-care in r/r AML(RAPID-01) | recruiting | Phase 2 | 88 | ETH ZurichOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT06355583 | Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial(MAST) | recruiting | Phase 2 | 50 | Imperial College LondonOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT06911710 | The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors(CAR-T) | recruiting | Phase 1 / Phase 2 | 90 | Tianjin Medical University General HospitalOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06022003 | Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia(OGILAR) | recruiting | Phase 2 | 33 | French Innovative Leukemia OrganisationOTHER | 1 | Mar 24, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 24, 2025source: clinicaltrials